Blood pressure j-curve: Current concepts

Current Hypertension Reports

Volumn 14, Issue 6, 2012, Pages 556-566

  Banach, Maciej ^a,b   Aronow, Wilbert S ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Antihypertensive treatment; Blood pressure; CAD; Cardiovascular risk; Coronary artery disease; Diabetes; Elderly; High risk populations; Hypertension; Hypotensive therapy; J curve; Left ventricle hypertrophy; LVH

Indexed keywords

ANTIHYPERTENSIVE AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INDAPAMIDE; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; TELMISARTAN; TRANDOLAPRIL; VERAPAMIL;

ACUTE CORONARY SYNDROME; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE J CURVE; BODY MASS; BRADYCARDIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY BLOOD FLOW; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FAINTNESS; HEART ARRHYTHMIA; HEART INFARCTION; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; LIFE EXPECTANCY; MORBIDITY; MORTALITY; ORTHOSTATIC HYPOTENSION; PRESSURE VOLUME CURVE; QUALITY OF LIFE; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE;

ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DIASTOLE; HUMANS; HYPERTENSION; PATIENT SELECTION; RISK FACTORS; SYSTOLE;

EID: 84870561433     PISSN: 15226417     EISSN: 15343111     Source Type: Journal    
DOI: 10.1007/s11906-012-0314-3     Document Type: Article

References (79)

1. Banach M, Aronow WS. Hypertension therapy in the older adultsdo we know the answers to all the questions? The status afterpublication of the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. J Hum Hypertens 2012; DOI: 10.1038/jhh.2012.3.
2. Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol. 2006;22:553-5.
3. Bielecka-Dabrowa A, Aronow WS, Rysz J, Banach M. The Rise and Fall of Hypertension: Lessons Learned from Eastern Europe. Curr Cardiovasc Risk Rep. 2011;5:174-9.
4. Barylski M, Malyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney -what was new in 2011? Arch Med Sci. 2011;7(6):1055-66.
5. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfield MJ, Cifkova R, Clément D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-58.
6. Banach M, Kjeldsen SE, Narkiewicz K. Editorial. Controversies in hypertension treatment. Curr Vasc Pharmacol. 2010;8:731-2.
7. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med. 2006;144:884-93.
8. Reboldi G, Gentile G, Manfreda VM, Angeli F, Verdecchia P. Tight blood pressure control in diabetes: evidence-based review of treatment targets in patients with diabetes. Curr Cardiol Rep. 2012;14:89-96.
9. Banach M, Michalska M, Kjeldsen SE, Malyszko J, Mikhailidis DP, Rysz J. What should be the optimal levels of blood pressure: Does the J-curve phenomenon really exist? Expert Opin Pharmacother. 2011;12(12):1835-44.
10. Gluba A, Bielecka A, Mikhailidis DP, Wong ND, Franklin SS, Rysz J, Banach M. An update on biomarkers of heart failure in hypertensive patients. J Hypertens. 2012;30:1681-9.
11. Kaplan NM. The diastolic J curve: alive and threatening. Hypertension. 2011;58(5):751-3.
12. Panjrath GS, Chaudhari S, Messerli FH. The J-point phenomenon in aggressive therapy of hypertension: new insights. Curr Atheroscler Rep. 2012;14(2):124-9.
13. Stewart IM. Relation of reduction in pressure to first myocardial infarction in patients receiving treatment for severe hypertension. Lancet. 1979;1:861-5.
14. Cruickshank JM, Thorp JM, Zacharias FJ. Benefits and potential harm of lowering high blood pressure. Lancet. 1987;1(8533):581-4.
15. D'Agostino RB, Belanger AJ, Kannel WB, Cruickshank JM. Relation of low diastolic blood pressure to coronary heart disease death in presence of myocardial infarction: the Framingham Study. BMJ. 1991;303:385-9.
16. Dudenbostel T, Oparil S. J curve in hypertension. Curr Cardiovasc Risk Rep. 2012;6:281-90.
17. Polese A, De Cesare N, Montorsi P, Fabbiocchi F, Guazzi M, Loaldi A, Guazzi MD. Upward shift of the lower range of coronary flow autoregulation in hypertensive patients with hypertrophy of the left ventricle. Circulation. 1991;83:845-53.
18. Okonski P, Banach M, Rysz J, Barylski M, Irzmanski R, Piechota M, Zaslonka J. L-arginine improves hemodynamic function and coronary flow in an experimental model of ischemia-reperfusion injury. Ann Transplant. 2006;11(1):28-34.
19. Ma J, Qian J, Ge J, Zeng X, Sun A, Chang S, Chen Z, Zou Y. Changes in left ventricular ejection fraction and coronary flow reserve after coronary microembolization. Arch Med Sci. 2012;8(1):63-9.
20. Williams B, Lindholm LH, Sever P. Systolic pressure is all that matters. Lancet. 2008;371:2219-21.
21. Zanchetti A, Grassi G, Mancia G. When should antihypertensive drug treatment be initiated and to what levels should systolic blood pressure be lowered? A critical appraisal. J Hypertens. 2009;27:923-34.
22. Marschner IC, Simes RJ, Keech A. Biases in the identification of risk factor thresholds and J-curves. Am J Epidemiol. 2007;166:824-31.
23. Kalantar-Zadeh K, Block G, Horwich T, Fonarow G. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439-44.
24. Sarwar N, Gao P, Seshasai SR, Gobin R, Kaptoge S, DiAngelantonio E, et al. Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet. 2010;375:2215-22.
25. Hansson L for the BBB Study Group. The BBB Study: The effect of intensified antihypertensive treatment on the level of blood pressure, side effects, morbidity and mortality in "well-treated" hypertensive patients. Blood Press. 1994;3:248-54.
26. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Ménard J, Rahn KH, Wedel H, Westerling S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet. 1998;351(9118):1755-62.
27. Cruickshank JM. Hypertension Optimal Treatment (HOT) trial. Lancet. 1998;352:573-4.
28. Hedner T, Oparil S, Narkiewicz K, Kjeldsen SE. The J-curve phenomenon revisited. Blood Press. 2009;18:168-70.
29. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, Hua T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet. 2004;363:2022-3.
30. Messerli FH, Mancia G, Weber MA, Kjeldsen SE, Holzhauer B, Hua TA, et al. Low blood pressure is associated with increased cardiovascular morbidity (J-shaped curve) in treated hypertensive patients with increased cardiovascular risk: The VALUE Randomized Trial. J Am Coll Cardiol. 2009;53(Suppl A):A46.
31. Sleight P, Redon J, Verdecchia P, Mancia G, Gao P, Fagard R, Schumacher H, Weber M, Böhm M, Williams B, Pogue J, Koon T, Yusuf S. ONTARGET investigators. Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study. J Hypertens. 2009;27:1360-9.
32. Mancia G, Schumacher H, Redon J, Verdecchia P, Schmieder R, Jennings G, et al. Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in ONTARGET. Circulation. 2011;124:1727-36.
33. Banach M, Rysz J. Current problems in hypertension and nephrology. Expert Opin Pharmacother. 2010;11:2575-8.
34. Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, Ganau A, Mureddu G, Pede S, Maggioni AP, Lucci D, Reboldi G. Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525-33.
35. Pepine CJ, Handberg EM, Cooper-DeHoff RM,Marks RG, Kowey P, Messerli FH, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, ParmleyWW. INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003;290:2805-16.
36. Bangalore S, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. J-curve revisited: an analysis of the Treating to New Targets (TNT) Trial. J Am Coll Cardiol. 2009;53:A217.
37. Bangalore S, Messerli FH, Wun CC, Zuckerman AL, DeMicco D, Kostis JB, LaRosa JC. Treating to New Targets Steering Committee and Investigators. J-curve revisited: An analysis of blood pressure and cardiovascular events in the Treating to NewTargets (TNT) Trial. Eur Heart J. 2010;31:2897-908.
38. Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP. PROVE IT-TIMI 22 Trial Investigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascular events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010;122:2142-51. Very important study in patients with acute coronary syndromes suggesting that low BP, especially <110/70 mmHg, may be very harmful for this group of patients.
39. Dorresteijn JA, van derGraafY, SpieringW, GrobbeeDE, Bots ML, Visseren FL. Secondary Manifestations of Arterial Disease Study Group. Relation between blood pressure and vascular events and mortality in patients with manifest vascular disease: J-curve revisited. Hypertension. 2012;59:14-21. One of the most current trials (SMART) in patients with symptomatic vascular disease, which confirmed that a J-curve relationship (increased risk of CVevents) was observed above and below the nadir of 143/82 mmHg. A similar nonlinear relationship was also found for DBP and all-cause mortality..
40. Bangalore S, Kumar S, Volodarskiy A, Messerli FH. Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart 2012; (in press).
41. Tryniszewski W, Kusmierczyk J, Maziarz Z, Gos R, Mikhailidis DP, Banach M, Rysz J, Pesudovs K. Correlation of the severity of diabetic retinopathy and the heart muscle perfusion in patients with type 2 diabetes. J Diabetes Complicat. 2011;25(4):253-7.
42. Cooper-DeHoff RM, Gong Y, Handberg EM, Bavry AA, Denardo SJ, Bakris GL, Pepine CJ. Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA. 2010;304:61-8. A retrospective analysis of the INVEST study, which revealed that this risk of CV events was also observed in diabetic patients with SBP below 115 mmHg.
43. The ACCORD Study Group. Effects of Intensive Blood-Pressure Control in Type 2 Diabetes Mellitus. N Engl J Med. 2010;362:1575-85. One of the most anticipated trials, which could have finally confirmed the J-curve relationship in diabetic patients. However, due to some limitations the interpretation of the study is not unequivocal.
44. Nilsson PM. ACCORD and risk-factor control in type 2 diabetes. N Engl J Med. 2010;362:1628-30.
45. Cooper-DeHoff RM, Egelund EF, Pepine CJ. Blood pressure lowering in patients with diabetes -one level might not fit all. Nat Rev Cardiol. 2011;8:42-9.
46. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ, Collaborative Study Group. Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol. 2005;16:2170-9.
47. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-97.
48. Redon J, Mancia G, Sleight P, Schumacher H, Gao P, Pogue J, Fagard R, Verdecchia P, Weber M, Böhm M, Williams B, Yusoff K, Teo K, Yusuf S. ONTARGET Investigators. Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial). J Am Coll Cardiol. 2012;59:74-83.
49. Vamos EP, Harris M, Millett C, Pape UJ, Khunti K, Curcin V, Molokhia M, Majeed A. Association of systolic and diastolic blood pressure and all cause mortality in people with newlydiagnosed type 2 diabetes: retrospective cohort study. BMJ. 2012;345:e5567. One of the most recent trials investigating the J-shaped relationship in DM patients. Analysing 126,092 adult patients from the United Kingdom General Practice Research Database, it showed that intensive BP lowering (<130/80) was associated with an increased risk of all-cause mortality.
50. Banach M, Aronow WS. Should we have any doubts about hypertension therapy in elderly patients?: ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Pol Arch Med Wewn. 2011;121:253-7.
51. Global Health Risks. Mortality and burden of disease attributable to selected major risks. World Health Organization 2009
52. Athyros VG, Giouleme O, Ganotakis ES, Elisaf M, Tziomalos K, Vassiliadis T, Liberopoulos EN, Theocharidou E, Karagiannis A, Mikhailidis DP. Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study. Arch Med Sci. 2011;7:796-805.
53. Aronow WS, Banach M. Ten most important things to learn from the ACCF/AHA 2011 expert consensus document on hypertension in the elderly. Blood Press. 2012;21:3-5.
54. Vokó Z, Bots ML, Hofman A, Koudstaal PJ, Witteman JC, Breteler MM. J-shaped relation between blood pressure and stroke in treated hypertensives. Hypertension. 1999;34:1181-5.
55. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in The Elderly Program. JAMA. 1991;265:3255-64.
56. Pastor-Barriuso R, Banegas JR, Damian J, Appel LJ, Guallar E. Systolic blood pressure, diastolic blood pressure, and pulse pressure: an evaluation of their joint effect on mortality. Ann Intern Med. 2003;139:731-9.
57. Staessen JA, Thijisq L, Fagard R, Celis H, BirkenhägerWH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G,McCormack P, Nachev C,O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847-57.
58. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80years of age or older. N Engl J Med. 2008;358:1887-98.
59. JATOS Study Group. Principal results of the Japanese trial to assess optimal systolic blood pressure in elderly hypertensive patients (JATOS). Hypertens Res. 2008;31:2115-27.
60. Ogihara T, Saruta T, Rakugi H,Matsuoka H, Shimamoto K, Shimada K, Imai Y, Kikuchi K, Ito S, Eto T, Kimura G, Imaizumi T, Takishita S, Ueshima H. Valsartan in Elderly Isolated Systolic Hypertension Study Group. Target blood pressure for treatment of isolated systolic hypertension in the elderly: Valsartan in Elderly Isolated Systolic Hypertension Study. Hypertension. 2010;56:196-202.
61. Oates DJ, Berlowitz DR, Glickman ME, Silliman RA, Borzecki AM. Blood pressure and survival in the oldest old. J Am Geriatr Soc. 2007;55(3):383-8.
62. Denardo SJ, Gong Y, Nichols WW, et al. Blood pressure and outcomes in very old hypertensive coronary artery disease patients: an INVEST Substudy. Am J Med. 2010;123(8):719-26. A subanalysis of the INVEST trial on 2,180 old (>80 years) participants, which confirmed age-dependent J-shaped relationships between on-treatment SBP (nadir: 110-140 mmHg) and DBP (nadir: 70-75 mmHg) and the primary outcome (all-cause mortality, nonfatal MI or nonfatal stroke).
63. Ogihara T, Matsuoka H, Rakugi H. Practitioner's trial on the efficacy of antihypertensive treatment in elderly patients with hypertension II (PATE-hypertension II study) in Japan. Geriatr Gerontol Int. 2011;11(4):414-21.
64. Okin PM, Hille DA, Kjeldsen SE, Dahlöf B, Devereux RB. Impact of lower achieved blood pressure on outcomes in hypertensive patients. J Hypertens. 2012;30:802-10. A subanalysis of LIFE study, where the authors found that SBP =130 mmHg was not associated with lower CV risk (in comparison to the group with SBP of 131 to 141 mmHg) and was associated with a significantly increased (29%) risk of death and a trend towards increased CV mortality.
65. Banach M, Bhatia V, Feller MA, Mujib M, Desai RV, Ahmed MI, Guichard JL, Aban I, Love TE, Aronow WS, White M, Deedwania P, Fonarow G, Ahmed A. Relation of baseline systolic blood pressure and long-term outcomes in ambulatory patients with chronic mild to moderate heart failure. Am J Cardiol. 2011;107:1208-14. This is one of the few studies suggesting a Jshape relationship while lowering SBP below 120 mmHg in patients with chronic heart failure.
66. Desai RV, Banach M, Ahmed MI, Mujib M, Aban I, Love TE, White M, Fonarow G, Deedwania P, Aronow WS, Ahmed A. Impact of baseline systolic blood pressure on long-term outcomes in patients with advanced chronic systolic heart failure (insights from the BEST trial). Am J Cardiol. 2010;106(2):221-7.
67. Norris K, Bourgoigne J, Gassman J, Hebert L, et al. Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension AASK (Trial). Am J Kidney Dis. 2006;48:739-51.
68. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-60.
69. Aronow WS. What should the optimal blood pressure goal be in patients with diabetes mellitus or chronic kidney disease? Arch Med Sci. 2012;8:399-402.
70. Agarwal R. Blood pressure components and the risk for end-stage renal disease and death in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(4):830-7.
71. Piotrowski G, Banach M, Gerdts E, Mikhailidis DP, Hannam S, Gawor R, Stasiak A, Rysz J, Gawor Z. Left atrial size in hypertension and stroke. J Hypertens. 2011;29:1988-93.
72. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ. 2009;338:1665-83. Optimal Blood Pressure And Cholesterol Targets For Preventing Recurrent Stroke In Hypertensives (ESH-CHL-SHOT). Clinical-Trials.gov Identifier: NCT01563731. The First Study That Aimed To Investigate The Optimal Blood Pressure Levels In Patients After Stroke TIA (as Well As The J-shaped Relationship In This Group Of Patients).
73. Zanchetti A. Blood pressure targets of antihypertensive treatment: up and down the J-shaped curve. Eur Heart J. 2010;31:2837-40.
74. Athyros VG, Hatzitolios AI, Karagiannis A, Savopoulos C, Katsiki N, TziomalosK, PapagianniA,Kakafika A,Gossios TD,Mikhailidis DP, IMPERATIVE Collaborative Group. IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis. Arch Med Sci. 2011;7(6):984-92. Systolic Blood Pressure Intervention Trial (SPRINT). Clinical-Trials.gov Identifier: NCT01206062.
75. Sethi A, Arora RR. Ambulatory blood pressure as a predictor of cardiovascular risk. Arch Med Sci. 2009;5:3-9.
76. Stepien M, Banach M, Jankowski P, Rysz J. Clinical implications of non-invasive measurement of central aortic blood pressure. Curr Vasc Pharmacol. 2010;8:747-52.
77. Lai HM, Aronow WS, Mercando AD, Kalen P, Desai HV, Gandhi K, Sharma M, Amin H, Lai TM. Risk factor reduction in progression of angiographic coronary artery disease. Arch Med Sci. 2012;8(3):444-8.
78. ZanchettiA,ManciaG, Black HR,Oparil S,Waeber B, Schmieder RE, Bakris GL,Messerli FH, Kjeldsen SE, Ruilope LM. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009;27:673-9.
79. Grassi G, Seravalle G, Trevano FQ, Dell'Oro R, Mancia G. Blood pressure control and antihypertensive treatment. Curr Vasc Pharmacol. 2012;10:506-11.